Konrad Glund
Keine laufenden Positionen mehr
Profil
Konrad Glund is the founder of Vivoryon Therapeutics NV, which was founded in 1997.
He held the title of Chief Executive Officer from 2006 to 2018.
Dr. Glund is also the founder of IFB Halle GmbH.
He previously worked as Vice President-Corporate Development at Prosidion Ltd.
and as a Principal at Martin-Luther-Universität Halle-Wittenberg.
Dr. Glund earned a doctorate degree from Martin-Luther-Universität Halle-Wittenberg.
Ehemalige bekannte Positionen von Konrad Glund
| Unternehmen | Position | Ende |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Vorstandsvorsitzender | 30.04.2018 |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
| IFB Halle GmbH | Vorstandsvorsitzender | - |
Ausbildung von Konrad Glund
| Martin-Luther-Universität Halle-Wittenberg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| IFB Halle GmbH | |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
